Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
Date:10/1/2010

llular immunotherapy. It is designed to be an active cellular immunotherapy. Active cellular immunotherapy is designed to stimulate a T-cell response to cancer cells. An immune response is started by a specialized class of immune system cells called antigen-presenting cells (APCs). APCs take up antigens from their surroundings and process the antigens into fragments that are then displayed on the APC's surface. Once displayed, these antigens can be recognized by specific classes of immune cells called T lymphocytes (T-cells), which are activated as a result of their engagement with APCs and combat disease by seeking antigen-bearing cells directly. PROVENGE is designed to target the prostate cancer antigen prostatic acid phosphatase (PAP), an antigen that is expressed in more than 95 percent of all prostate cancers.

About Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factor
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... steam over the five years to 2014. Industry operators ... first time during the period, as well as establish ... growth is due in large part to its novelty; ... 2005. Nevertheless, in that time, industry operators have been ...
(Date:9/19/2014)... 19, 2014 Follow us ... surgical techniques, and immunosuppressant drugs to prevent rejection, ... several chronic diseases related to the heart, kidneys, ... tissue transplantation have phenomenally revolutionized the survival rate ... today represents a pivotal medical intervention for thousands ...
(Date:9/19/2014)... well in infertile land, and bear many beans that ... because most legumes have a symbiotic relationship with bacteria, ... and then supply the host plant with ammonia as ... called nodules in their roots. However, if too many ... growth of the plants, because the energy cost of ...
(Date:9/19/2014)... Lifeinsure.biz has released a new blog post presenting 5 ... medical examinations. , Life insurance riders can drive ... more advantageous. Clients can read the newly released blog ... a no medical exam life insurance policy. , ... purchase, however it is more expensive. Life insurance rates ...
(Date:9/19/2014)... September 19, 2014 Ticket Down ... for his 2014 concert tour. Concertgoers can add ... business, there are a handful of artists that are considered ... in Saginaw, MichIgan, Wonder has been a force in the ... in the music business, he has released 23 studio albums, ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Long-distance communication from leaves to roots 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3
... devastating brain injury that has wiped out many of ... other peoples feelings and intentions, according to a joint ... Centre for Aging and the Brain, and York Universitys ... published in the Nov. 23, 2007 issue of Science, ...
... sleepiness, experts say, , , THURSDAY, Nov. 22 (HealthDay News) ... Thanksgiving feast aren,t rare, and experts say a number ... , It may have to do with the traditional ... a chemical known to promote sleepiness, said Donna Arand, ...
... future treatment of breast cancer have been identified by a ... the online open access journal Breast Cancer Research may focus ... , A team led by Professor Mitch Dowsett, Head of ... London and Surrey, together with colleagues from the USA, Switzerland ...
... CHICAGO, Nov. 21 The Female Health Company,(Amex: ... The Wall Street,Analyst Forum 18th Annual Analyst Conference on ... York City (on 43rd Street between 5th and,6th). The ... will,present at the conference at 11:50 a.m. Eastern Time ...
... mean more ozone, and more strain on hearts, researchers ... temperatures and high ozone levels work together to boost ... , They believe that global warming -- which brings ... the number of people who die of cardiovascular events. ...
... PICK: Pregnant women pass on the effects of smoking ... effects on fetal development. A new study in mice ... Toronto, Canada, now adds the possibility that smoking before ... of female offspring to the long list of possible ...
Cached Medicine News:Health News:People with rare type of memory loss still sensitive to others, study shows 2Health News:People with rare type of memory loss still sensitive to others, study shows 3Health News:There's More Than Turkey Behind Holiday Yawns 2Health News:Found in translation: Prioritizing research questions in breast cancer 2Health News:The Female Health Company to Present at Wall Street Analyst Forum Wednesday, November 28, 2007 2Health News:Global Warming May Trigger Rise in Heart Deaths 2Health News:Global Warming May Trigger Rise in Heart Deaths 3Health News:JCI table of contents: Nov. 21, 2007 2Health News:JCI table of contents: Nov. 21, 2007 3Health News:JCI table of contents: Nov. 21, 2007 4Health News:JCI table of contents: Nov. 21, 2007 5Health News:JCI table of contents: Nov. 21, 2007 6Health News:JCI table of contents: Nov. 21, 2007 7Health News:JCI table of contents: Nov. 21, 2007 8Health News:JCI table of contents: Nov. 21, 2007 9Health News:JCI table of contents: Nov. 21, 2007 10
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Target illumination for day and night testing. Glare luminance distance. The Optec 3500 remote control offers flexible positioning during test administration. Each vision tester includes 12 tests sli...
... The CSV- lOOOHGT instrument provides standardized glare testing. ... Vectorvision test faces for the evaluation of glare ... is precisely calibrated to simulate two on-coming halogen ... feet. The glare level can be adjusted to ...
Ruler S/Steel....
Medicine Products: